|
Quality of Foreign Trial Data May Ease Sponsor, Regulator Concerns
Drugmakers and regulators can be more confident about the rigor of trial data coming from emerging markets as the quality of studies appears to be on par with trials in more research-savvy, developed nations, a new study concludes.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives